Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
Month
1
2
3
4
5
6
7
8
9
10
11
12
2024.04.08
Boan Biotech Completes Phase 3 Clinical Trial for Its Aflibercept intravitreous Injection BA9101 in China, Planning to file a BLA
2024.03.26
Boan Biotech Announces 2023 Financial Results
2024.03.08
Phase 3 Clinical Trial Completed in China for Boan Biotech’s Dulaglutide Injection BA5101. BLA to be filed soon
30
2024-01
Boan Biotech Authorizes Zencore Biologics to Use Its BA-HIEXcell® Stable Cell Line Development Platform
29
2024-01
Boan Biotech Authorizes Joincare to Exclusively Develop and Commercialize Its BA2101 for Respiratory Indications in Chinese Mainland
25
2024-01
2 CLDN 18.2-Targeted Drugs Granted ODD for Gastric Cancer in US
18
2024-01
Boan Biotech Obtains ANVISA GMP Certification
15
2024-01
All Subjects Enrolled for Intl Phase 3 Study of Boan’s Denosumab
28
2023-12
Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA
30
2023-10
1st Patient Enrolled in Phase 3 Study of Boan’s Nivolumab
1
2
3
4
5